381 related articles for article (PubMed ID: 17139378)
21. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
22. Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis.
Darwish NHE; Godugu K; Mousa SA
Thromb Res; 2021 Apr; 200():109-114. PubMed ID: 33582600
[TBL] [Abstract][Full Text] [Related]
23. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Naumnik B; Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
[TBL] [Abstract][Full Text] [Related]
24. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; Dunwiddie CT; Perrone MH
Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):908-14. PubMed ID: 9633930
[TBL] [Abstract][Full Text] [Related]
28. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.
Amirkhosravi A; Mousa SA; Amaya M; Meyer T; Davila M; Robson T; Francis JL
Methods Mol Biol; 2010; 663():241-59. PubMed ID: 20617422
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
30. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Spencer FA; Ball SP; Zhang Q; Liu L; Benoit S; Becker RC
J Thromb Thrombolysis; 2000 Apr; 9(3):223-8. PubMed ID: 10728020
[TBL] [Abstract][Full Text] [Related]
31. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
32. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
34. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
35. A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis.
Chen Y; Peng J; Han M; Omar M; Hu D; Ke X; Lu N
J Drug Target; 2015 May; 23(4):335-46. PubMed ID: 25541466
[TBL] [Abstract][Full Text] [Related]
36. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Ludwig RJ; Alban S; Bistrian R; Boehncke WH; Kaufmann R; Henschler R; Gille J
Thromb Haemost; 2006 Mar; 95(3):535-40. PubMed ID: 16525583
[TBL] [Abstract][Full Text] [Related]
37. Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Goertz L; Schneider SW; Desch A; Mayer FT; Koett J; Nowak K; Karampinis I; Bohlmann MK; Umansky V; Bauer AT
Oncotarget; 2016 Oct; 7(42):68527-68545. PubMed ID: 27602496
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
[TBL] [Abstract][Full Text] [Related]
39. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
[TBL] [Abstract][Full Text] [Related]
40. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
